Ascendis Pharma A/S $ASND Shares Bought by UBS Group AG

UBS Group AG grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 57.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 308,190 shares of the biotechnology company’s stock after buying an additional 112,986 shares during the quarter. UBS Group AG’s holdings in Ascendis Pharma A/S were worth $65,718,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Avoro Capital Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 2.6% during the third quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after acquiring an additional 130,000 shares during the period. Capital International Investors grew its holdings in Ascendis Pharma A/S by 0.4% during the third quarter. Capital International Investors now owns 3,060,616 shares of the biotechnology company’s stock worth $608,481,000 after acquiring an additional 13,685 shares during the period. Wellington Management Group LLP grew its holdings in Ascendis Pharma A/S by 95.9% during the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after acquiring an additional 880,836 shares during the period. Perceptive Advisors LLC acquired a new position in Ascendis Pharma A/S during the second quarter worth about $166,367,000. Finally, Principal Financial Group Inc. grew its holdings in Ascendis Pharma A/S by 2,722.9% during the third quarter. Principal Financial Group Inc. now owns 793,677 shares of the biotechnology company’s stock worth $157,791,000 after acquiring an additional 765,561 shares during the period.

Ascendis Pharma A/S Trading Up 3.5%

ASND stock opened at $228.71 on Tuesday. Ascendis Pharma A/S has a one year low of $150.89 and a one year high of $250.74. The firm has a market capitalization of $14.27 billion, a PE ratio of -51.98 and a beta of 0.41. The firm has a 50-day moving average of $231.29 and a two-hundred day moving average of $218.40.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The business had revenue of $290.38 million for the quarter, compared to analysts’ expectations of $285.35 million. On average, equities research analysts anticipate that Ascendis Pharma A/S will post 4.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. The Goldman Sachs Group restated a “buy” rating and issued a $255.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $300.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, January 21st. Jefferies Financial Group assumed coverage on shares of Ascendis Pharma A/S in a research report on Monday, March 16th. They issued a “buy” rating and a $290.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and issued a $273.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $291.56.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.